Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Gemtuzumab · Mylotarg

Antibody-drug conjugate · Cytotoxic, directed at CD33 · developed by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer

Approved FDA
1 Registered trials

What is Gemtuzumab?

Gemtuzumab ozogamicin is an antibody-drug conjugate in which an anti-CD33 antibody is linked to the cytotoxic agent N-acetyl gamma calicheamicin. It binds CD33 on tumor cells, is internalized, and releases the calicheamicin derivative, which causes double-strand DNA breaks and cell death. It is used in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Mylotarg
Drug type
Antibody-drug conjugate
Targets
CD33
Mechanism
Cytotoxic, directed at CD33
Pathways
DNA double-strand breaks, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.
In trials of
KURA
FDA status
Approved as Mylotarg, BLA761060 · FDA label
UNII
93NS566KF7

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 19, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06448013 Phase 1 Acute Myeloid Leukemia Recruiting KURA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia

Other drugs acting on CD33

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.